Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $409.0752W HIGH $609.35
Volume
1.44 M
Value Traded
340.46 M
Short % Float
6.76%
-1.65%Week
+5.12%1 Month
-2.61%3 Month
-6.81%6 Month
+196.46%5 Year
+8,321.19%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
22.85 B
EPS (TTM)
30.56
P/E Ratio
17.43
Ent. Value
19.05 B
Total Shares
42.87 M
Float Shares
41.45 M
Insiders
3.35%
Institutions
97.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
UTHR Catalyst Timeline
Dated clinical, regulatory and corporate events for United Therapeutics Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for United Therapeutics Corporation
195Total events
23Upcoming
53Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲IP Litigation RulingIP / Competition
Delaware District Court finds Liquidia infringes two claims of United Therapeutics' inhaled treprostinil PH-ILD patent
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
▼Equity OfferingCorporate
United Therapeutics enters $477.6M Accelerated Share Repurchase agreement with Citibank to utilize remainder of $2.0B buyback authorization
▲FDA Filing AcceptedTyvaso (treprostinil)ApprovedRegulatory Filing
FDA accepts supplemental NDA for nebulized Tyvaso in IPF
Idiopathic Pulmonary Fibrosissource ↗
▲Primary Endpoint MetTyvaso (treprostinil)ApprovedClinical Data
Combined TETON-1 and TETON-2 met primary efficacy endpoint
idiopathic pulmonary fibrosissource ↗
▲Enrollment CompleteTyvaso (treprostinil)ApprovedTrial
Enrollment complete in TETON-PPF study
progressive pulmonary fibrosissource ↗
◆Oral PresentationRalinepagFiledPresentation
Treatment with Ralinepag Improves Outcomes in Patients with Connective Tissue Disease Associated with Pulmonary Arterial Hypertension: Results from the Phase 3 ADVANCE OUTCOMES Study
pulmonary arterial hypertension (PAH)source ↗
◆Oral PresentationTyvaso (treprostinil)ApprovedPresentation
Early and Rapid Treprostinil Titration Improves Right Ventricular Ejection Fraction at 12 Months in Pulmonary Arterial Hypertension: ARTISAN Interim Analysis
pulmonary arterial hypertension (PAH)source ↗
▲FDA Filing AcceptedRalinepagFiledRegulatory Filing
FDA accepted NDA for ralinepag
pulmonary arterial hypertensionsource ↗
▲Primary Endpoint MetRalinepagFiledClinical Data
ADVANCE OUTCOMES met primary endpoint
pulmonary arterial hypertensionsource ↗
●PublicationRalinepagFiledPresentation
Results published in The Lancet
pulmonary arterial hypertensionsource ↗
▲Enrollment CompleteTyvaso (treprostinil)ApprovedTrial
Full enrollment of TETON-PPF study of nebulized Tyvaso in PPF (754 patients)
progressive pulmonary fibrosis (PPF)source ↗
▲PublicationRalinepagFiledPresentation
Full ADVANCE OUTCOMES results published in The Lancet
pulmonary arterial hypertension (PAH)source ↗
▲FDA ApprovalLungFXApprovedFDA Decision
FDA approval of LungFX device for centralized ex vivo lung perfusion
Ex Vivo Lung Perfusionsource ↗
▲FDA ApprovalFDA Decision
FDA approval of LungFX Device for centralized ex vivo lung perfusion
centralized ex vivo lung perfusionsource ↗
◆Management ChangeCorporate
Professor Raymond Dwek's term as director expires at 2026 Annual Meeting
●NDA SubmissionRalinepagFiledRegulatory Filing
United Therapeutics submitted NDA for ralinepag to FDA
pulmonary arterial hypertension (PAH)source ↗
●sNDA SubmissionTyvaso (treprostinil)ApprovedRegulatory Filing
sNDA submitted to FDA for nebulized treprostinil to treat IPF
idiopathic pulmonary fibrosis (IPF)source ↗
●sNDA SubmissionTyvaso (treprostinil)ApprovedRegulatory Filing
sNDA submitted to FDA in June 2026 to add IPF to nebulized Tyvaso label
idiopathic pulmonary fibrosis (IPF)source ↗
◆Full ResultsTyvaso (treprostinil)ApprovedClinical Data
TETON-1 study of Tyvaso published in NEJM and presented at ATS 2026
idiopathic pulmonary fibrosissource ↗
◆Oral PresentationRalinepagFiledPresentation
ADVANCE OUTCOMES study of Ralinepag presented at ATS 2026
pulmonary arterial hypertensionsource ↗
▲Full ResultsRalinepagFiledClinical Data
Full results of ADVANCE OUTCOMES presented at ATS 2026
pulmonary arterial hypertensionsource ↗
▲Oral PresentationRalinepagFiledPresentation
ADVANCE OUTCOMES results presented at ATS Breaking News session
pulmonary arterial hypertensionsource ↗
▲Primary Endpoint MetRalinepagFiledClinical Data
ADVANCE OUTCOMES met primary endpoint: 55% risk reduction in clinical worsening
pulmonary arterial hypertensionsource ↗
▲Secondary Endpoint DataRalinepagFiledClinical Data
Secondary endpoints met: NT-proBNP reduction and 6MWD improvement
pulmonary arterial hypertensionsource ↗
◆Oral PresentationPresentation
Presentation at RBC Capital Markets Global Healthcare Conference
◆Trial InitiationRalinepagFiledTrial
Development plans announced for ralinepag DPI in pulmonary hypertension and fibrosis
pulmonary hypertension and fibrosissource ↗
●Development Candidate NominationRalinepagFiledPreclinical
Development plans announced for ralinepag DPI
pulmonary hypertension and fibrosissource ↗
◆Oral PresentationPresentation
Oral presentation on prolonged pig-to-baboon lung xenograft survival with 11GE pigs
xenotransplantationsource ↗
◆Oral PresentationPresentation
Oral presentation on novel serum assays for complement monitoring in cardiac xenotransplantation
xenotransplantationsource ↗
◆Poster PresentationPresentation
Poster on lung transplantation outcomes in ILD patients with/without PH using linked data
lung transplantation in ILDsource ↗
◆Poster PresentationPresentation
Poster on TEE sizing of genetically modified porcine hearts for xenotransplantation
xenotransplantationsource ↗
◆Oral PresentationPresentation
Mini oral presentation on remote centralized EVLP for lung allograft recovery
lung transplantationsource ↗
◆Oral PresentationPresentation
Oral presentation on ML-based prediction of donor lung acceptance using EVLP deflation videos
lung transplantationsource ↗
◆Poster PresentationTyvaso (treprostinil)ApprovedPresentation
ARTISAN interim analysis poster: early high-dose treprostinil reduces mPAP and improves right heart function in PAH
pulmonary arterial hypertensionsource ↗
▲RMATmiroliverELAPDesignation
FDA Regenerative Medicine Advanced Therapy designation for miroliverELAP
acute liver failuresource ↗
◆Full ResultsmiroliverELAPClinical Data
Full study results to be presented and published
acute liver failuresource ↗
●NDA SubmissionTyvaso (treprostinil)ApprovedRegulatory Filing
NDA submitted for Nebulized Tyvaso in IPF
IPFsource ↗
▲Primary Endpoint MetTyvaso (treprostinil)ApprovedClinical Data
TETON-1 pivotal study of Tyvaso meets primary endpoint for IPF
idiopathic pulmonary fibrosissource ↗
Past FDA Catalysts and PDUFA Decisions
How UTHR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-06 | Nebulized (inhaled) treprostinil (TETON program) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B65 / 100
Pipeline Score
$4.6B
Pipeline Value
$12.5B
Commercial Value
Overvalued
Valuation Signal
7
Drugs Scored
0.4x
rNPV / MCap
Top 5%
Mid Cap(rank 34 of 658)
Percentile Rank
United Therapeutics Corporation holds a solid B-grade pipeline (65/100), with $5.5B risk-adjusted pipeline value, led by Tyvaso (treprostinil) in COPD (Chronic Obstructive Pulmonary Disease) (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $3.2B x 4.0 = $12.5B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Tyvaso DPI | $1.3B | $1.2B | +14.3% |
| Nebulized Tyvaso | $521M | $620M | -16% |
| Orenitram | $514M | $466M | +10.3% |
| Remodulin | $507M | $536M | -5.4% |
| Unituxin | $229M | $245M | -6.6% |
| Adcirca | $27M | $24M | +12% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyvaso (treprostinil) Small moleculeNCT05943535 | Progressive Pulmonary Fibrosis | Phase 3 | RECRUITING | 698 | Nov 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every UTHR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ralinepag | pulmonary arterial hypertension | Phase 3 | 2026-08-28 | clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue diseaseRead More | United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ROTHBLATT MARTINE ADirector, Officer (Chairperson & CEO) | Option | 9,500 333,943 held | $117.76 | 10/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in UTHR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 13.5 % (-11.8 %) | 1.51 B | 2.78 M | 5.62% ( 147.78 K) |
UTHR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How UTHR ranks across every disease it competes in
Competitive Position is a premium feature
See how UTHR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialUTHR News
UTHR▲ +5.4%on this news
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
United Therapeutics Corporation has successfully prevailed in a patent litigation case against Liquidia Technologies, with the U.S. District Court for Delaware ruling that Liquidia infringed on two of United Therapeutics' patents. The patents pertain to the use of inhaled treprostinil for treating pulmonary hypertension associated with interstitial lung disease. This ruling reinforces United Therapeutics' intellectual property rights in this area.
Read more →UTHRUnited Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
United Therapeutics Corporation has announced an Accelerated Share Repurchase (ASR) agreement with Citibank to repurchase approximately $477.6 million of its common stock. This move utilizes part of the company's previously authorized $2 billion share repurchase program. The decision reflects the company's confidence in its stock value and financial position.
Read more →UTHRUnited Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation announced that the FDA has accepted its supplemental New Drug Application for nebulized Tyvaso (treprostinil) Inhalation Solution aimed at treating idiopathic pulmonary fibrosis (IPF). This marks a significant step as the drug is currently investigational for this condition. The FDA's review is expected to conclude by late April 2027.
Read more →UTHRUnited Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
United Therapeutics Corporation has announced its participation in four upcoming investor conferences. CEO Martine Rothblatt will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026. This engagement highlights the company's commitment to investor relations and transparency.
Read more →UTHRUnited Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
United Therapeutics Corporation has announced its participation in two major European congresses in 2026. The company will present four oral and four poster presentations at the European Society of Cardiology Congress in Munich and the European Respiratory Society Congress in Barcelona. These presentations will highlight advancements in their commercial and development portfolio.
Read more →UTHRUnited Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
United Therapeutics Corporation announced that the FDA has accepted its New Drug Application for ralinepag, aimed at treating pulmonary arterial hypertension (PAH). The FDA has set a target action date of June 24, 2027, for the review. Currently, ralinepag remains investigational and has not been approved for any indication.
Read more →UTHRUnited Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
United Therapeutics Corporation has announced the full enrollment of its TETON-PPF study, which evaluates the inhalation solution Tyvaso® (treprostinil) for treating progressive pulmonary fibrosis (PPF). A total of 754 patients have been enrolled in the study, reflecting a significant demand for new treatment options in this area.
Read more →UTHRUnited Therapeutics Corporation Reports Second Quarter 2026 Financial Results
United Therapeutics Corporation reported its financial results for Q2 2026, revealing a two percent decrease in total revenues to $783.3 million compared to the same quarter in 2025. Despite the decline, the company highlighted the submission of two significant NDAs for ralinepag, aimed at addressing rare pulmonary diseases. This reflects their ongoing commitment to innovation in this specialized field.
Read more →UTHRUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
United Therapeutics Corporation announced the publication of the ADVANCE OUTCOMES study results for Ralinepag in The Lancet. The study demonstrated that Ralinepag reduced the risk of clinical worsening events by 55% in patients with pulmonary arterial hypertension (PAH). However, Ralinepag remains investigational and has not yet received FDA approval.
Read more →UTHRUnited Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
United Therapeutics Corporation has appointed Victor Dzau, M.D., to its Board of Directors, effective July 22, 2026. Dr. Dzau has a distinguished background, having served as President of the National Academy of Medicine and Chancellor for Health Affairs at Duke University. His extensive experience is expected to contribute positively to the company's strategic direction.
Read more →UTHRUnited Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
United Therapeutics Corporation has announced the date for its second quarter 2026 financial results, which will be released on August 5, 2026. The company will also host a public webcast at 9:00 a.m. Eastern Time on the same day. This event will provide insights into the company's financial performance.
Read more →UTHRUnited Therapeutics Corporation Acquires Thymmune Therapeutics
United Therapeutics Corporation has announced the acquisition of Thymmune Therapeutics. This strategic move aims to enhance United Therapeutics' capabilities and offerings in the biopharmaceutical sector. The acquisition is expected to leverage Thymmune's innovative technologies, potentially strengthening United Therapeutics' market presence.
Read more →UTHRThe Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026
United Therapeutics Corporation has been named the Visionary/Presenting Sponsor of National Patch Day 2026, a movement aimed at supporting children and young adults facing serious health challenges. This partnership will enhance the initiative's ability to provide encouragement and connection to families in need. National Patch Day operates year-round, distributing patches that symbolize hope and resilience.
Read more →UTHRUnited Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
United Therapeutics Corporation has received FDA approval for its LungFX™ device, designed for centralized ex vivo lung perfusion. This innovative technology aims to enhance the preservation of lungs for transplantation, potentially improving patient outcomes. The approval marks a significant advancement in lung transplant procedures.
Read more →UTHRJefferies Global Healthcare Conference
United Therapeutics is scheduled to participate in the Jefferies Global Healthcare Conference on June 3, 2026. This event is part of a series of upcoming presentations and financial results announcements. The company has a history of active participation in various healthcare conferences, showcasing its commitment to transparency and investor relations.
Read more →UTHRUnited Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
United Therapeutics Corporation is scheduled to present at the Jefferies Global Healthcare Conference. The details regarding the presentation or any specific topics to be discussed were not provided in the article. This event is an opportunity for the company to engage with investors and stakeholders in the healthcare sector.
Read more →UTHRUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
United Therapeutics Corporation announced the publication of the TETON-1 study of Tyvaso in The New England Journal of Medicine. The study findings were also presented at the ATS 2026 conference. This marks a significant step for the company in showcasing its research efforts.
Read more →UTHRUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
United Therapeutics Corporation announced the presentation of the ADVANCE OUTCOMES study of Ralinepag at the ATS 2026 conference. The study's findings were highlighted, showcasing the company's ongoing commitment to advancing treatments for pulmonary arterial hypertension. Further details about the study's outcomes and implications were not disclosed in the announcement.
Read more →UTHRUnited Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation is scheduled to present at the RBC Capital Markets Global Healthcare Conference. The presentation will provide insights into the company's current initiatives and future directions. Details regarding the timing and content of the presentation have not been disclosed in the article.
Read more →UTHRUnited Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
United Therapeutics Corporation presented new data from their studies TETON-1 and ADVANCE OUTCOMES, along with additional research on pulmonary hypertension and pulmonary fibrosis at the ATS 2026 conference. The details of the findings were not disclosed in the article. This presentation highlights the company's ongoing commitment to advancing research in these areas.
Read more →About United Therapeutics Corporation
Headquarters1000 SPRING ST, SILVER SPRING, MD, 20910
BIOPHARMAWATCH ELITE PLUS
Trade the next UTHR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime